NASDAQ:AXSM   Axsome Therapeutics, Inc
AXSM clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system, it is accelerating the completion of the ADVANCE-1 Phase 2/3 trial of AXS-05 in patients with Alzheimer’s disease agitation to ensure the safety of this vulnerable patient population during the COVID-19 pandemic. i expect that this end of the month its increasing thoroughly. Are you guys ready to get through resistance? why not?

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.